Biomaxima SA (BMX) Stock Analysis | Price, Returns, Financials & Key Metrics

Mojo Score Change: Biomaxima SA has changed its score on 01 Dec 2025. Click here to unlock latest mojo score!

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

High Debt Company with a Debt to Equity ratio (avg) at times

High Debt Company with a Debt to Equity ratio (avg) at times

High Debt company with Weak Long Term Fundamental Strength

The company has declared Negative results for the last 8 consecutive quarters

With ROE of 1.49%, it has a fair valuation with a 1.14 Price to Book Value

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

PLN 48 Million (Micro Cap)

P/E

54.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.30

Return on Equity

1.39%

Price to Book

1.02

Revenue and Profits:

Net Sales:

15 Million

(Quarterly Results - Mar 2025)

Net Profit:

1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-13.7%

6 Months

-20.21%

1 Year

-4.51%

2 Years

-28.96%

3 Years

-54.58%

4 Years

-55.19%

5 Years

-57.79%

Biomaxima SA for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

4.88%

EBIT Growth (5y)

-40.97%

EBIT to Interest (avg)

11.03

Debt to EBITDA (avg)

2.19

Net Debt to Equity (avg)

0.28

Sales to Capital Employed (avg)

0.85

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

26.53%

ROE (avg)

24.44%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.14

EV to EBIT

68.60

EV to EBITDA

15.85

EV to Capital Employed

1.11

EV to Sales

1.20

PEG Ratio

0.21

Dividend Yield

ROCE (Latest)

1.25%

ROE (Latest)

1.49%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is -3.77% vs 22.31% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is -40.00% vs 433.33% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "15.30",
          "val2": "15.90",
          "chgp": "-3.77%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1.60",
          "val2": "1.80",
          "chgp": "-11.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.60",
          "val2": "1.00",
          "chgp": "-40.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "46.70%",
          "val2": "56.50%",
          "chgp": "-0.98%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 13.03% vs -67.48% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -16.67% vs -97.92% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "52.90",
          "val2": "46.80",
          "chgp": "13.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "3.80",
          "val2": "1.80",
          "chgp": "111.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.00",
          "val2": "0.60",
          "chgp": "66.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.50",
          "val2": "0.60",
          "chgp": "-16.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "8.10%",
          "val2": "-13.60%",
          "chgp": "2.17%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ

Mar'25

Dec'24

Change(%)

Net Sales

15.30

15.90

-3.77%

Operating Profit (PBDIT) excl Other Income

1.60

1.80

-11.11%

Interest

0.30

Exceptional Items

0.00

Consolidate Net Profit

0.60

1.00

-40.00%

Operating Profit Margin (Excl OI)

46.70%

56.50%

-0.98%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2025 is -3.77% vs 22.31% in Dec 2024

Consolidated Net Profit

QoQ Growth in quarter ended Mar 2025 is -40.00% vs 433.33% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

52.90

46.80

13.03%

Operating Profit (PBDIT) excl Other Income

3.80

1.80

111.11%

Interest

1.00

0.60

66.67%

Exceptional Items

0.00

Consolidate Net Profit

0.50

0.60

-16.67%

Operating Profit Margin (Excl OI)

8.10%

-13.60%

2.17%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 13.03% vs -67.48% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -16.67% vs -97.92% in Dec 2023

All Annual Results

Company CV

About Biomaxima SA

Biomaxima SA

Pharmaceuticals & Biotechnology

BioMaxima SA is a Poland-based company active in the laboratory diagnostics sector. It manufactures and distributes reagents and equipment for the laboratory diagnosis. It produces reagents for the in vitro diagnosis. The main product groups offered by BioMaxima include: diagnostic reagents and analyzers for clinical biochemistry; rapid tests and readers for detecting infectious diseases, cancer markers, cardiac markers and drugs of abuse; urine analysis systems; hematology analyzers and reagents; ion-selective analyzers and reagents; reagents and immunological analyzers of cardiac markers; glucometers; analyzers for gasometric tests and critical blood parameters tests. The Company supplies hospitals and laboratories in Poland, as well as in Lithuania, Latvia, Romania and France. On March 20, 2014, the Company merged with its wholly owned subsidiary Cebo Sp z o o.

Company Coordinates

Company Details

Ul. Vetterow 5 , LUBLIN None : 20-277

Tel: 48 81 440837148 81 4408371

http://biomaxima.com

Registrar Details